Makers of Zantac stopping distribution due to cancer concerns
Posted Sep 18, 2019 11:59 am.
Last Updated Sep 18, 2019 12:00 pm.
OTTAWA – The maker of a popular heartburn medication is halting distribution amid concerns of a cancer-causing chemical.
Sandoz, the makers of Zantac made the decision days after regulators in the U.S. and Europe found NDMA, a known carcinogen, in the medications.
[2/2] RECALL: Sandoz is voluntarily recalling prescription oral #ranitidine products while work continues internationally to assess #NDMA in drugs: https://t.co/yeFWEqHhPQ
— Health Canada and PHAC (@GovCanHealth) September 18, 2019
The chemical was found in brand name and generic forms of Zantac, which the key ingredient is Ranitidine.
The company also issued a recall for Canada for the following products: Sandoz Ranitidine 150 mg tablet and 300 mg tablet.
Health Canada is also asking all companies to stop distribution of the medicine.
